HHS Accountability Project publication

On Tuesday, August 2, 2022, EPPC Fellow Rachel N. Morrison and Senior Fellow Roger Severino met with federal government officials…

In line with the Biden administration’s equity and gender identity policy priorities, the Department of Education (ED) has proposed new regulations on Title IX of the Civil Rights Act of 1972, which prohibits sex discrimination in federally funded educational programs and activities.

On Friday, July 15, 2022, EPPC Fellow Rachel N. Morrison met with federal government officials to discuss concerns over an…

While the FDA pushes vaccines on all age groups—claiming that a dire COVID-19 public health emergency still exists—the White House appears perfectly comfortable with the CDC’s April 1 decision to terminate a public health authority meant to prevent the spread of COVID-19 across our borders.

The White House, HHS, DOJ, and other federal agencies have been issuing statements and policy positions under existing law at a steady pace.

The brief explains that there is no medical consensus regarding an authoritative standard of care for gender dysphoria or transitioning treatments and that such treatments can lead to serious harms, especially for children.

Under President Biden, our own federal agencies don’t agree if we are in a health emergency or not.

President Joe Biden issued yet another executive order promoting his administration’s “LGBTQI+” policies.

EPPC has filed a friend-of-court brief in support of a lawsuit challenging a mandate by the U.S. Department of Health and Human Services requiring healthcare providers under the guise of nondiscrimination to perform and provide insurance coverage for “gender-transition procedures.”

There is no need for a primary series of COVID-19 vaccines for children. The young have a decreased benefit from COVID-19 vaccination but are also at a greater safety risk. Plus, many children have already had COVID and have the benefits of naturally acquired immunity.

EPPC Fellow David Gortler submitted a comment to the FDA for a public advisory meeting of the Vaccines and Related Biological Products Advisory Committee opposing Emergency Use Authorization requests by Moderna and Pfizer for Covid vaccines for children.

EPPC Fellow David Gortler submitted a public comment to the Food and Drug Administration on a public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee to discuss an Emergency Use Authorization (EUA) request by Novavax for a vaccine to prevent COVID-19 in individuals 18 years of age and older.